BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

75 related articles for article (PubMed ID: 13129395)

  • 1. Conditionally cleavable radioimmunoconjugates: a novel approach for the release of radioisotopes from radioimmunoconjugates.
    Beeson C; Butrynski JE; Hart MJ; Nourigat C; Matthews DC; Press OW; Senter PD; Bernstein ID
    Bioconjug Chem; 2003; 14(5):927-33. PubMed ID: 13129395
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of linker chemistry on the pharmacokinetics of radioimmunoconjugates.
    Quadri SM; Vriesendorp HM
    Q J Nucl Med; 1998 Dec; 42(4):250-61. PubMed ID: 9973840
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Site-specifically traced drug release and biodistribution of a paclitaxel-antibody conjugate toward improvement of the linker structure.
    Safavy A; Georg GI; Vander Velde D; Raisch KP; Safavy K; Carpenter M; Wang W; Bonner JA; Khazaeli MB; Buchsbaum DJ
    Bioconjug Chem; 2004; 15(6):1264-74. PubMed ID: 15546192
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Influence of the linker on the biodistribution and catabolism of actinium-225 self-immolative tumor-targeted isotope generators.
    Antczak C; Jaggi JS; LeFave CV; Curcio MJ; McDevitt MR; Scheinberg DA
    Bioconjug Chem; 2006; 17(6):1551-60. PubMed ID: 17105236
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pretargeted radioimmunotherapy in tumored mice using an in vivo 212Pb/212Bi generator.
    Su FM; Beaumier P; Axworthy D; Atcher R; Fritzberg A
    Nucl Med Biol; 2005 Oct; 32(7):741-7. PubMed ID: 16243650
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pretargeting with bispecific anti-renal cell carcinoma x anti-DTPA(In) antibody in 3 RCC models.
    van Schaijk FG; Oosterwijk E; Molkenboer-Kuenen JD; Soede AC; McBride BJ; Goldenberg DM; Oyen WJ; Corstens FH; Boerman OC
    J Nucl Med; 2005 Mar; 46(3):495-501. PubMed ID: 15750164
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Optimization of radioimmunotherapy of renal cell carcinoma: labeling of monoclonal antibody cG250 with 131I, 90Y, 177Lu, or 186Re.
    Brouwers AH; van Eerd JE; Frielink C; Oosterwijk E; Oyen WJ; Corstens FH; Boerman OC
    J Nucl Med; 2004 Feb; 45(2):327-37. PubMed ID: 14960657
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biodistribution and therapeutic efficacy of (125/131)I-, (186)Re-, (88/90)Y-, or (177)Lu-labeled monoclonal antibody MN-14 to carcinoembryonic antigen in mice with small peritoneal metastases of colorectal origin.
    Koppe MJ; Bleichrodt RP; Soede AC; Verhofstad AA; Goldenberg DM; Oyen WJ; Boerman OC
    J Nucl Med; 2004 Jul; 45(7):1224-32. PubMed ID: 15235070
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vitro and in vivo characterization of 177Lu-huA33: a radioimmunoconjugate against colorectal cancer.
    Almqvist Y; Steffen AC; Tolmachev V; Divgi CR; Sundin A
    Nucl Med Biol; 2006 Nov; 33(8):991-8. PubMed ID: 17127172
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A novel bispecific, trivalent antibody construct for targeting pancreatic carcinoma.
    Gold DV; Goldenberg DM; Karacay H; Rossi EA; Chang CH; Cardillo TM; McBride WJ; Sharkey RM
    Cancer Res; 2008 Jun; 68(12):4819-26. PubMed ID: 18559529
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pretargeting with labeled bivalent peptides allowing the use of four radionuclides: (111)In, (131)I, (99m)Tc, and (188)Re.
    van Schaijk FG; Oosterwijk E; Soede AC; Oyen WJ; McBride WJ; Griffiths GL; Goldenberg DM; Corstens FH; Boerman OC
    Clin Cancer Res; 2003 Sep; 9(10 Pt 2):3880S-5S. PubMed ID: 14506186
    [TBL] [Abstract][Full Text] [Related]  

  • 12. (177)Lu/ (90)Y intermediate-affinity monoclonal antibodies targeting EGFR and HER2/c-neu: preparation and preclinical evaluation.
    Beckford Vera DR; Eigner S; Eigner Henke K; Leyva MontaƱa R; Melichar F; Beran M
    Recent Results Cancer Res; 2013; 194():301-17. PubMed ID: 22918766
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Assessment of the radiochemical design of antibodies with a metabolizable linkage for target-selective radioactivity delivery.
    Arano Y; Wakisaka K; Akizawa H; Ono M; Kawai K; Nakayama M; Sakahara H; Konishi J; Saji H
    Bioconjug Chem; 1998; 9(4):497-506. PubMed ID: 9667952
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Enhanced tumour uptake of radiolabelled antibodies by hyperthermia: Part I: Timing of injection relative to hyperthermia.
    Hauck ML; Zalutsky MR
    Int J Hyperthermia; 2005 Feb; 21(1):1-11. PubMed ID: 15764347
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vitro and in vivo targeting properties of iodine-123- or iodine-131-labeled monoclonal antibody 14C5 in a non-small cell lung cancer and colon carcinoma model.
    Burvenich I; Schoonooghe S; Cornelissen B; Blanckaert P; Coene E; Cuvelier C; Mertens N; Slegers G
    Clin Cancer Res; 2005 Oct; 11(20):7288-96. PubMed ID: 16243799
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative cellular catabolism and retention of astatine-, bismuth-, and lead-radiolabeled internalizing monoclonal antibody.
    Yao Z; Garmestani K; Wong KJ; Park LS; Dadachova E; Yordanov A; Waldmann TA; Eckelman WC; Paik CH; Carrasquillo JA
    J Nucl Med; 2001 Oct; 42(10):1538-44. PubMed ID: 11585870
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Optimizing bispecific antibody pretargeting for use in radioimmunotherapy.
    Sharkey RM; Karacay H; Richel H; McBride WJ; Rossi EA; Chang K; Yeldell D; Griffiths GL; Hansen HJ; Goldenberg DM
    Clin Cancer Res; 2003 Sep; 9(10 Pt 2):3897S-913S. PubMed ID: 14506188
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Improved targeting of pancreatic cancer: experimental studies of a new bispecific antibody, pretargeting enhancement system for immunoscintigraphy.
    Cardillo TM; Karacay H; Goldenberg DM; Yeldell D; Chang CH; Modrak DE; Sharkey RM; Gold DV
    Clin Cancer Res; 2004 May; 10(10):3552-61. PubMed ID: 15161715
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tumor delivery and in vivo processing of disulfide-linked and thioether-linked antibody-maytansinoid conjugates.
    Erickson HK; Widdison WC; Mayo MF; Whiteman K; Audette C; Wilhelm SD; Singh R
    Bioconjug Chem; 2010 Jan; 21(1):84-92. PubMed ID: 19891424
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Contribution of linker stability to the activities of anticancer immunoconjugates.
    Alley SC; Benjamin DR; Jeffrey SC; Okeley NM; Meyer DL; Sanderson RJ; Senter PD
    Bioconjug Chem; 2008 Mar; 19(3):759-65. PubMed ID: 18314937
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.